CytoDyn to Present at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on January 23, 2020 Jan 22, 2020 1:16pm EST
Impressive Results Continue from CytoDyn’s Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC Jan 22, 2020 5:00am EST
CytoDyn Appoints Alan Timmins as New Independent Director and Chair of the Audit Committee Jan 21, 2020 5:00am EST
CytoDyn Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer Jan 13, 2020 5:00am EST
CytoDyn Reports Early, But Strong Positive Clinical Responses for Two Patients, One in Metastatic Breast Cancer and One in Metastatic Triple-Negative Breast Cancer Trials Dec 23, 2019 6:00am EST
CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV Dec 17, 2019 4:36pm EST
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial Dec 03, 2019 8:00am EST
CytoDyn Reports Strong Positive Preclinical Data to Demonstrate Potential of Leronlimab in Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Humanized Mouse Model Nov 21, 2019 6:00am EST
